The overall ratings of nine biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
CEL-SCI Corporation’s (CVM) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. CEL-SCI is developing new immune system based treatments for cancer and infectious diseases. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, CVM also gets F’s. For more information, get Portfolio Grader’s complete analysis of CVM stock.
EPIRUS Biopharmaceuticals, Inc. (EPRS) experiences a ratings drop this week, going from last week’s C to a D. The stock also gets an F in Earnings Revisions. To get an in-depth look at EPRS, get Portfolio Grader’s complete analysis of EPRS stock.
Ohr Pharmaceutical Inc (OHRP) is having a tough week. The company’s rating falls from a C to a D. Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. The stock gets F’s in Earnings Revisions and Equity. For more information, get Portfolio Grader’s complete analysis of OHRP stock.
The rating of Trius Therapeutics, Inc. (TSRX) declines this week from a C to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.
Vical Incorporated’s (VICL) rating weakens this week, dropping to a D versus last week’s C. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of VICL stock.
Synergy Pharmaceuticals, Inc. (SGYP) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The stock gets F’s in Equity and Cash Flow. As of Sept. 2, 2015, 20.6% of outstanding Synergy Pharmaceuticals, Inc. shares were held short. To get an in-depth look at SGYP, get Portfolio Grader’s complete analysis of SGYP stock.
Slipping from a D to an F rating, Verastem, Inc. (VSTM) takes a hit this week. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. As of Sept. 2, 2015, 11.2% of outstanding Verastem, Inc. shares were held short. In the past week, the volume of trades plummeted to half the previous rate. For more information, get Portfolio Grader’s complete analysis of VSTM stock.
This week, Celldex Therapeutics, Inc. (CLDX) drops from a C to a D rating. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock also rates an F in Equity. As of Sept. 2, 2015, 16.9% of outstanding Celldex Therapeutics, Inc. shares were held short. To get an in-depth look at CLDX, get Portfolio Grader’s complete analysis of CLDX stock.
This is a rough week for Trevena, Inc. (TRVN). The company’s rating falls to D from the previous week’s C. The stock gets F’s in Equity and Cash Flow. Shares of the stock have been changing hands at an unusually rapid pace, up 18472.5% from the week prior. For more information, get Portfolio Grader’s complete analysis of TRVN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
